Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM) / Andrea Perrelli, Parisa Fatehbasharzad, Valerio Benedetti, Chiara Ferraris, Marco Fontanella, Elisa De Luca, Mauro Moglianetti, Luigi Battaglia, Saverio Francesco Retta
ABSTRACT Introduction : Cerebrovascular diseases encompass various disorders of the brain vasculature, such as ischemic/hemorrhagic strokes, aneurysms, and vascular malformations, also affecting the central nervous system leading to a large variety of transient or permanent neurological disorders. They represent major causes of mortality and long-term disability worldwide, and some of them can be inherited, including Cerebral Cavernous Malformation (CCM), an autosomal dominant cerebrovascular disease linked to mutations in CCM1/KRIT1, CCM2, or CCM3/PDCD10 genes. Areas covered : Besides marked clinical and etiological heterogeneity, some commonalities are emerging among distinct cerebrovascular diseases, including key pathogenetic roles of oxidative stress and inflammation, which are increasingly recognized as major disease hallmarks and therapeutic targets. This review provides a comprehensive overview of the different clinical features and common pathogenetic determinants of cerebrovascular diseases, highlighting major challenges, including the pressing need for new diagnostic and therapeutic strategies, and focusing on emerging innovative features and promising benefits of nanomedicine strategies for early detection and targeted treatment of such diseases. Expert opinion : Specifically, we describe and discuss the multiple physico-chemical features and unique biological advantages of nanosystems, including nanodiagnostics, nanotherapeutics, and nanotheranostics, that may help improving diagnosis and treatment of cerebrovascular diseases and neurological comorbidities, with an emphasis on CCM disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Expert opinion on drug delivery - 18(2021), 7, Seite 849-876 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Perrelli, Andrea [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (28 p) |
|---|
| doi: |
10.1080/17425247.2021.1873273 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011113995 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011113995 | ||
| 003 | DE-627 | ||
| 005 | 20231109210010.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425247.2021.1873273 |2 doi | |
| 035 | |a (DE-627)KFL011113995 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/17425247.2021.1873273 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Perrelli, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM) |c Andrea Perrelli, Parisa Fatehbasharzad, Valerio Benedetti, Chiara Ferraris, Marco Fontanella, Elisa De Luca, Mauro Moglianetti, Luigi Battaglia, Saverio Francesco Retta |
| 264 | 1 | |c 2021 | |
| 300 | |a 1 Online-Ressource (28 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction : Cerebrovascular diseases encompass various disorders of the brain vasculature, such as ischemic/hemorrhagic strokes, aneurysms, and vascular malformations, also affecting the central nervous system leading to a large variety of transient or permanent neurological disorders. They represent major causes of mortality and long-term disability worldwide, and some of them can be inherited, including Cerebral Cavernous Malformation (CCM), an autosomal dominant cerebrovascular disease linked to mutations in CCM1/KRIT1, CCM2, or CCM3/PDCD10 genes. Areas covered : Besides marked clinical and etiological heterogeneity, some commonalities are emerging among distinct cerebrovascular diseases, including key pathogenetic roles of oxidative stress and inflammation, which are increasingly recognized as major disease hallmarks and therapeutic targets. This review provides a comprehensive overview of the different clinical features and common pathogenetic determinants of cerebrovascular diseases, highlighting major challenges, including the pressing need for new diagnostic and therapeutic strategies, and focusing on emerging innovative features and promising benefits of nanomedicine strategies for early detection and targeted treatment of such diseases. Expert opinion : Specifically, we describe and discuss the multiple physico-chemical features and unique biological advantages of nanosystems, including nanodiagnostics, nanotherapeutics, and nanotheranostics, that may help improving diagnosis and treatment of cerebrovascular diseases and neurological comorbidities, with an emphasis on CCM disease | ||
| 653 | |a Central nervous system (CNS) | ||
| 653 | |a cerebrovascular diseases | ||
| 653 | |a cerebral cavernous malformation (CCM) | ||
| 653 | |a inflammation | ||
| 653 | |a oxidative stress | ||
| 653 | |a nanosystems | ||
| 653 | |a nanodiagnostics | ||
| 653 | |a nanotherapeutics | ||
| 653 | |a nanotheranostics | ||
| 653 | |a nose-to-brain delivery | ||
| 700 | 1 | |a Fatehbasharzad, Parisa |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetti, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraris, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Fontanella, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Moglianetti, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Battaglia, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Retta, Saverio Francesco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug delivery |d Abingdon : Taylor & Francis Group, 2004 |g 18(2021), 7, Seite 849-876 |h Online-Ressource |w (DE-627)KFL000006114 |w (DE-600)2232223-1 |w (DE-576)302970223 |x 1744-7593 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2021 |g number:7 |g pages:849-876 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/17425247.2021.1873273 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2021 |e 7 |h 849-876 | ||